Ilumya Solution for Injection, Prefilled Syringe 100mg/ml

Manufacturer
Sun Pharmaceutical Industries (Europe) B.V.(NETHERLANDS)

Registraction Number
MAL24126016ACZ

Content:
Each prefilled syringe contains:
-Tildrakizumab: 100 mg
Indications:
Moderate-to-Severe Plaque Psoriasis: Used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy2.
Instructions:
Dosage: The recommended dose is 100 mg at Weeks 0, 4, and every 12 weeks thereafter2.
Administration: Administer by subcutaneous injection. Ensure proper evaluation and immunization prior to treatment initiation2.